Community-Acquired Pneumonia Treatment in Kidney Transplant Patients

Preferred Antibiotic Regimens

The Infectious Diseases Society of America recommends using a respiratory fluoroquinolone, such as levofloxacin 750 mg daily or moxifloxacin 400 mg daily, as monotherapy for kidney transplant patients with penicillin allergy and community-acquired pneumonia, due to the immunosuppressing condition requiring more robust coverage 1, 2
For penicillin-allergic patients, the guidelines recommend respiratory fluoroquinolone as the preferred alternative 3, 1
The American Thoracic Society guidelines state that immunosuppressing conditions, such as kidney transplant, require either a respiratory fluoroquinolone or a β-lactam plus macrolide combination 3

Levofloxacin 750 mg orally daily for 5-7 days is recommended for outpatient treatment 1, 2
Moxifloxacin 400 mg orally daily for 5-7 days is recommended for outpatient treatment 1, 2
Levofloxacin 750 mg IV daily is recommended for hospitalized non-ICU patients 1, 2
Moxifloxacin 400 mg IV daily is recommended for hospitalized non-ICU patients 1, 2

For kidney transplant patients with impaired renal function, levofloxacin requires dose adjustment: 750 mg loading dose, then 500 mg every 48 hours if CrCl 20-49 mL/min 1
Moxifloxacin requires no dose adjustment for kidney transplant patients with impaired renal function 1
The minimum treatment duration is 5 days and until afebrile for 48-72 hours with no more than one sign of clinical instability 1, 2
Typical duration for uncomplicated community-acquired pneumonia is 5-7 days 1, 2

Never use macrolide monotherapy in immunosuppressed patients, as it provides inadequate coverage for typical bacterial pathogens 1
Do not delay antibiotic administration beyond 8 hours, as this increases 30-day mortality by 20-30% 1, 2
Obtain blood and sputum cultures before initiating antibiotics in all hospitalized patients 1